ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Monoclonal Antibody Drugs for Cancer Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-11V16446
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Monoclonal Antibody Drugs for Cancer Market Research Report 2023
BUY CHAPTERS

Global Monoclonal Antibody Drugs for Cancer Market Research Report 2025

Code: QYRE-Auto-11V16446
Report
May 2025
Pages:98
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol–Myers Squibb
Amgen Inc
Astrazeneca plc
Merck
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer Inc
Regeneron
Innovent
Hengrui Medicine

The global market for Monoclonal Antibody Drugs for Cancer was valued at US$ 103210 million in the year 2024 and is projected to reach a revised size of US$ 181270 million by 2031, growing at a CAGR of 8.5% during the forecast period.

Monoclonal Antibody Drugs for Cancer Market

Monoclonal Antibody Drugs for Cancer Market

Monoclonal antibodies (MABs) are a type of targeted drug therapy. These drugs recognise and find specific proteins on cancer cells. There are many different MABs to treat cancer. They work in different ways to kill the cancer cell or stop it from growing.
The Therapeutic Antibodies Drug Market is driven by the remarkable potential of therapeutic antibodies to treat a diverse array of diseases, from cancer and autoimmune disorders to infectious diseases. Monoclonal antibodies have gained prominence as highly targeted and effective therapeutic agents that can modulate the immune system, neutralize pathogens, and inhibit disease-associated proteins. As precision medicine and biopharmaceutical innovations continue to advance, the demand for therapeutic antibodies grows. Innovations in antibody design, engineering, and manufacturing technologies further contribute to market expansion. Nevertheless, a significant challenge for this market is the need to address high production costs, optimize therapeutic antibody development processes, and navigate complex regulatory pathways while ensuring accessibility and affordability for patients. Overcoming manufacturing complexities, managing research and development costs, and addressing regulatory standards are ongoing challenges. Additionally, the market faces competition from small molecules and other biologic therapies, necessitating continuous research and development efforts to unlock the full therapeutic potential of therapeutic antibodies. Striking a balance between providing safe, effective, and accessible therapeutic antibody drugs while addressing scientific and regulatory challenges is essential for the continued growth of the Therapeutic Antibodies Drug Market.
This report aims to provide a comprehensive presentation of the global market for Monoclonal Antibody Drugs for Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Monoclonal Antibody Drugs for Cancer.
The Monoclonal Antibody Drugs for Cancer market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Monoclonal Antibody Drugs for Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Monoclonal Antibody Drugs for Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Monoclonal Antibody Drugs for Cancer Market Report

Report Metric Details
Report Name Monoclonal Antibody Drugs for Cancer Market
Accounted market size in year US$ 103210 million
Forecasted market size in 2031 US$ 181270 million
CAGR 8.5%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Blood-related Cancer
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, Merck KGaA, Seagen, Eli Lilly, Ono Pharmaceutical, Pfizer, Regeneron, Innovent, Hengrui Medicine
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Monoclonal Antibody Drugs for Cancer company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Monoclonal Antibody Drugs for Cancer Market growing?

Ans: The Monoclonal Antibody Drugs for Cancer Market witnessing a CAGR of 8.5% during the forecast period 2025-2031.

What is the Monoclonal Antibody Drugs for Cancer Market size in 2031?

Ans: The Monoclonal Antibody Drugs for Cancer Market size in 2031 will be US$ 181270 million.

Who are the main players in the Monoclonal Antibody Drugs for Cancer Market report?

Ans: The main players in the Monoclonal Antibody Drugs for Cancer Market are Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, Merck KGaA, Seagen, Eli Lilly, Ono Pharmaceutical, Pfizer, Regeneron, Innovent, Hengrui Medicine

What are the Application segmentation covered in the Monoclonal Antibody Drugs for Cancer Market report?

Ans: The Applications covered in the Monoclonal Antibody Drugs for Cancer Market report are Lung Cancer, Breast Cancer, Prostate Cancer, Blood-related Cancer, Other

What are the Type segmentation covered in the Monoclonal Antibody Drugs for Cancer Market report?

Ans: The Types covered in the Monoclonal Antibody Drugs for Cancer Market report are Mouse-derived Antibodies, Chimeric Antibodies, Humanized Antibodies

Recommended Reports

Antibody Cancer Drugs

Targeted Cancer Therapy

Cancer Treatment Modalities

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Monoclonal Antibody Drugs for Cancer Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Mouse-derived Antibodies
1.2.3 Chimeric Antibodies
1.2.4 Humanized Antibodies
1.3 Market by Application
1.3.1 Global Monoclonal Antibody Drugs for Cancer Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Prostate Cancer
1.3.5 Blood-related Cancer
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Monoclonal Antibody Drugs for Cancer Market Perspective (2020-2031)
2.2 Global Monoclonal Antibody Drugs for Cancer Growth Trends by Region
2.2.1 Global Monoclonal Antibody Drugs for Cancer Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Monoclonal Antibody Drugs for Cancer Historic Market Size by Region (2020-2025)
2.2.3 Monoclonal Antibody Drugs for Cancer Forecasted Market Size by Region (2026-2031)
2.3 Monoclonal Antibody Drugs for Cancer Market Dynamics
2.3.1 Monoclonal Antibody Drugs for Cancer Industry Trends
2.3.2 Monoclonal Antibody Drugs for Cancer Market Drivers
2.3.3 Monoclonal Antibody Drugs for Cancer Market Challenges
2.3.4 Monoclonal Antibody Drugs for Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Monoclonal Antibody Drugs for Cancer Players by Revenue
3.1.1 Global Top Monoclonal Antibody Drugs for Cancer Players by Revenue (2020-2025)
3.1.2 Global Monoclonal Antibody Drugs for Cancer Revenue Market Share by Players (2020-2025)
3.2 Global Monoclonal Antibody Drugs for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Monoclonal Antibody Drugs for Cancer Revenue
3.4 Global Monoclonal Antibody Drugs for Cancer Market Concentration Ratio
3.4.1 Global Monoclonal Antibody Drugs for Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Monoclonal Antibody Drugs for Cancer Revenue in 2024
3.5 Global Key Players of Monoclonal Antibody Drugs for Cancer Head office and Area Served
3.6 Global Key Players of Monoclonal Antibody Drugs for Cancer, Product and Application
3.7 Global Key Players of Monoclonal Antibody Drugs for Cancer, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Monoclonal Antibody Drugs for Cancer Breakdown Data by Type
4.1 Global Monoclonal Antibody Drugs for Cancer Historic Market Size by Type (2020-2025)
4.2 Global Monoclonal Antibody Drugs for Cancer Forecasted Market Size by Type (2026-2031)
5 Monoclonal Antibody Drugs for Cancer Breakdown Data by Application
5.1 Global Monoclonal Antibody Drugs for Cancer Historic Market Size by Application (2020-2025)
5.2 Global Monoclonal Antibody Drugs for Cancer Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Monoclonal Antibody Drugs for Cancer Market Size (2020-2031)
6.2 North America Monoclonal Antibody Drugs for Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Monoclonal Antibody Drugs for Cancer Market Size by Country (2020-2025)
6.4 North America Monoclonal Antibody Drugs for Cancer Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Monoclonal Antibody Drugs for Cancer Market Size (2020-2031)
7.2 Europe Monoclonal Antibody Drugs for Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Monoclonal Antibody Drugs for Cancer Market Size by Country (2020-2025)
7.4 Europe Monoclonal Antibody Drugs for Cancer Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Monoclonal Antibody Drugs for Cancer Market Size (2020-2031)
8.2 Asia-Pacific Monoclonal Antibody Drugs for Cancer Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Monoclonal Antibody Drugs for Cancer Market Size by Region (2020-2025)
8.4 Asia-Pacific Monoclonal Antibody Drugs for Cancer Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Monoclonal Antibody Drugs for Cancer Market Size (2020-2031)
9.2 Latin America Monoclonal Antibody Drugs for Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Monoclonal Antibody Drugs for Cancer Market Size by Country (2020-2025)
9.4 Latin America Monoclonal Antibody Drugs for Cancer Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Monoclonal Antibody Drugs for Cancer Market Size (2020-2031)
10.2 Middle East & Africa Monoclonal Antibody Drugs for Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Monoclonal Antibody Drugs for Cancer Market Size by Country (2020-2025)
10.4 Middle East & Africa Monoclonal Antibody Drugs for Cancer Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Details
11.1.2 Johnson & Johnson Business Overview
11.1.3 Johnson & Johnson Monoclonal Antibody Drugs for Cancer Introduction
11.1.4 Johnson & Johnson Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
11.1.5 Johnson & Johnson Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Monoclonal Antibody Drugs for Cancer Introduction
11.2.4 Novartis Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
11.2.5 Novartis Recent Development
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Details
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Monoclonal Antibody Drugs for Cancer Introduction
11.3.4 Gilead Sciences Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
11.3.5 Gilead Sciences Recent Development
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Monoclonal Antibody Drugs for Cancer Introduction
11.4.4 Roche Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
11.4.5 Roche Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Details
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Monoclonal Antibody Drugs for Cancer Introduction
11.5.4 Bristol-Myers Squibb Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Amgen
11.6.1 Amgen Company Details
11.6.2 Amgen Business Overview
11.6.3 Amgen Monoclonal Antibody Drugs for Cancer Introduction
11.6.4 Amgen Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
11.6.5 Amgen Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Details
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Monoclonal Antibody Drugs for Cancer Introduction
11.7.4 AstraZeneca Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
11.7.5 AstraZeneca Recent Development
11.8 Merck & Co
11.8.1 Merck & Co Company Details
11.8.2 Merck & Co Business Overview
11.8.3 Merck & Co Monoclonal Antibody Drugs for Cancer Introduction
11.8.4 Merck & Co Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
11.8.5 Merck & Co Recent Development
11.9 Takeda
11.9.1 Takeda Company Details
11.9.2 Takeda Business Overview
11.9.3 Takeda Monoclonal Antibody Drugs for Cancer Introduction
11.9.4 Takeda Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
11.9.5 Takeda Recent Development
11.10 Merck KGaA
11.10.1 Merck KGaA Company Details
11.10.2 Merck KGaA Business Overview
11.10.3 Merck KGaA Monoclonal Antibody Drugs for Cancer Introduction
11.10.4 Merck KGaA Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
11.10.5 Merck KGaA Recent Development
11.11 Seagen
11.11.1 Seagen Company Details
11.11.2 Seagen Business Overview
11.11.3 Seagen Monoclonal Antibody Drugs for Cancer Introduction
11.11.4 Seagen Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
11.11.5 Seagen Recent Development
11.12 Eli Lilly
11.12.1 Eli Lilly Company Details
11.12.2 Eli Lilly Business Overview
11.12.3 Eli Lilly Monoclonal Antibody Drugs for Cancer Introduction
11.12.4 Eli Lilly Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
11.12.5 Eli Lilly Recent Development
11.13 Ono Pharmaceutical
11.13.1 Ono Pharmaceutical Company Details
11.13.2 Ono Pharmaceutical Business Overview
11.13.3 Ono Pharmaceutical Monoclonal Antibody Drugs for Cancer Introduction
11.13.4 Ono Pharmaceutical Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
11.13.5 Ono Pharmaceutical Recent Development
11.14 Pfizer
11.14.1 Pfizer Company Details
11.14.2 Pfizer Business Overview
11.14.3 Pfizer Monoclonal Antibody Drugs for Cancer Introduction
11.14.4 Pfizer Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
11.14.5 Pfizer Recent Development
11.15 Regeneron
11.15.1 Regeneron Company Details
11.15.2 Regeneron Business Overview
11.15.3 Regeneron Monoclonal Antibody Drugs for Cancer Introduction
11.15.4 Regeneron Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
11.15.5 Regeneron Recent Development
11.16 Innovent
11.16.1 Innovent Company Details
11.16.2 Innovent Business Overview
11.16.3 Innovent Monoclonal Antibody Drugs for Cancer Introduction
11.16.4 Innovent Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
11.16.5 Innovent Recent Development
11.17 Hengrui Medicine
11.17.1 Hengrui Medicine Company Details
11.17.2 Hengrui Medicine Business Overview
11.17.3 Hengrui Medicine Monoclonal Antibody Drugs for Cancer Introduction
11.17.4 Hengrui Medicine Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
11.17.5 Hengrui Medicine Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol–Myers Squibb
Amgen Inc
Astrazeneca plc
Merck
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer Inc
Regeneron
Innovent
Hengrui Medicine
List of Tables
 Table 1. Global Monoclonal Antibody Drugs for Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Mouse-derived Antibodies
 Table 3. Key Players of Chimeric Antibodies
 Table 4. Key Players of Humanized Antibodies
 Table 5. Global Monoclonal Antibody Drugs for Cancer Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Monoclonal Antibody Drugs for Cancer Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Monoclonal Antibody Drugs for Cancer Market Size by Region (2020-2025) & (US$ Million)
 Table 8. Global Monoclonal Antibody Drugs for Cancer Market Share by Region (2020-2025)
 Table 9. Global Monoclonal Antibody Drugs for Cancer Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 10. Global Monoclonal Antibody Drugs for Cancer Market Share by Region (2026-2031)
 Table 11. Monoclonal Antibody Drugs for Cancer Market Trends
 Table 12. Monoclonal Antibody Drugs for Cancer Market Drivers
 Table 13. Monoclonal Antibody Drugs for Cancer Market Challenges
 Table 14. Monoclonal Antibody Drugs for Cancer Market Restraints
 Table 15. Global Monoclonal Antibody Drugs for Cancer Revenue by Players (2020-2025) & (US$ Million)
 Table 16. Global Monoclonal Antibody Drugs for Cancer Market Share by Players (2020-2025)
 Table 17. Global Top Monoclonal Antibody Drugs for Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibody Drugs for Cancer as of 2024)
 Table 18. Ranking of Global Top Monoclonal Antibody Drugs for Cancer Companies by Revenue (US$ Million) in 2024
 Table 19. Global 5 Largest Players Market Share by Monoclonal Antibody Drugs for Cancer Revenue (CR5 and HHI) & (2020-2025)
 Table 20. Global Key Players of Monoclonal Antibody Drugs for Cancer, Headquarters and Area Served
 Table 21. Global Key Players of Monoclonal Antibody Drugs for Cancer, Product and Application
 Table 22. Global Key Players of Monoclonal Antibody Drugs for Cancer, Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global Monoclonal Antibody Drugs for Cancer Market Size by Type (2020-2025) & (US$ Million)
 Table 25. Global Monoclonal Antibody Drugs for Cancer Revenue Market Share by Type (2020-2025)
 Table 26. Global Monoclonal Antibody Drugs for Cancer Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 27. Global Monoclonal Antibody Drugs for Cancer Revenue Market Share by Type (2026-2031)
 Table 28. Global Monoclonal Antibody Drugs for Cancer Market Size by Application (2020-2025) & (US$ Million)
 Table 29. Global Monoclonal Antibody Drugs for Cancer Revenue Market Share by Application (2020-2025)
 Table 30. Global Monoclonal Antibody Drugs for Cancer Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 31. Global Monoclonal Antibody Drugs for Cancer Revenue Market Share by Application (2026-2031)
 Table 32. North America Monoclonal Antibody Drugs for Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 33. North America Monoclonal Antibody Drugs for Cancer Market Size by Country (2020-2025) & (US$ Million)
 Table 34. North America Monoclonal Antibody Drugs for Cancer Market Size by Country (2026-2031) & (US$ Million)
 Table 35. Europe Monoclonal Antibody Drugs for Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. Europe Monoclonal Antibody Drugs for Cancer Market Size by Country (2020-2025) & (US$ Million)
 Table 37. Europe Monoclonal Antibody Drugs for Cancer Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Asia-Pacific Monoclonal Antibody Drugs for Cancer Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Asia-Pacific Monoclonal Antibody Drugs for Cancer Market Size by Region (2020-2025) & (US$ Million)
 Table 40. Asia-Pacific Monoclonal Antibody Drugs for Cancer Market Size by Region (2026-2031) & (US$ Million)
 Table 41. Latin America Monoclonal Antibody Drugs for Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Latin America Monoclonal Antibody Drugs for Cancer Market Size by Country (2020-2025) & (US$ Million)
 Table 43. Latin America Monoclonal Antibody Drugs for Cancer Market Size by Country (2026-2031) & (US$ Million)
 Table 44. Middle East & Africa Monoclonal Antibody Drugs for Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Middle East & Africa Monoclonal Antibody Drugs for Cancer Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Middle East & Africa Monoclonal Antibody Drugs for Cancer Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Johnson & Johnson Company Details
 Table 48. Johnson & Johnson Business Overview
 Table 49. Johnson & Johnson Monoclonal Antibody Drugs for Cancer Product
 Table 50. Johnson & Johnson Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025) & (US$ Million)
 Table 51. Johnson & Johnson Recent Development
 Table 52. Novartis Company Details
 Table 53. Novartis Business Overview
 Table 54. Novartis Monoclonal Antibody Drugs for Cancer Product
 Table 55. Novartis Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025) & (US$ Million)
 Table 56. Novartis Recent Development
 Table 57. Gilead Sciences Company Details
 Table 58. Gilead Sciences Business Overview
 Table 59. Gilead Sciences Monoclonal Antibody Drugs for Cancer Product
 Table 60. Gilead Sciences Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025) & (US$ Million)
 Table 61. Gilead Sciences Recent Development
 Table 62. Roche Company Details
 Table 63. Roche Business Overview
 Table 64. Roche Monoclonal Antibody Drugs for Cancer Product
 Table 65. Roche Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025) & (US$ Million)
 Table 66. Roche Recent Development
 Table 67. Bristol-Myers Squibb Company Details
 Table 68. Bristol-Myers Squibb Business Overview
 Table 69. Bristol-Myers Squibb Monoclonal Antibody Drugs for Cancer Product
 Table 70. Bristol-Myers Squibb Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025) & (US$ Million)
 Table 71. Bristol-Myers Squibb Recent Development
 Table 72. Amgen Company Details
 Table 73. Amgen Business Overview
 Table 74. Amgen Monoclonal Antibody Drugs for Cancer Product
 Table 75. Amgen Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025) & (US$ Million)
 Table 76. Amgen Recent Development
 Table 77. AstraZeneca Company Details
 Table 78. AstraZeneca Business Overview
 Table 79. AstraZeneca Monoclonal Antibody Drugs for Cancer Product
 Table 80. AstraZeneca Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025) & (US$ Million)
 Table 81. AstraZeneca Recent Development
 Table 82. Merck & Co Company Details
 Table 83. Merck & Co Business Overview
 Table 84. Merck & Co Monoclonal Antibody Drugs for Cancer Product
 Table 85. Merck & Co Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025) & (US$ Million)
 Table 86. Merck & Co Recent Development
 Table 87. Takeda Company Details
 Table 88. Takeda Business Overview
 Table 89. Takeda Monoclonal Antibody Drugs for Cancer Product
 Table 90. Takeda Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025) & (US$ Million)
 Table 91. Takeda Recent Development
 Table 92. Merck KGaA Company Details
 Table 93. Merck KGaA Business Overview
 Table 94. Merck KGaA Monoclonal Antibody Drugs for Cancer Product
 Table 95. Merck KGaA Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025) & (US$ Million)
 Table 96. Merck KGaA Recent Development
 Table 97. Seagen Company Details
 Table 98. Seagen Business Overview
 Table 99. Seagen Monoclonal Antibody Drugs for Cancer Product
 Table 100. Seagen Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025) & (US$ Million)
 Table 101. Seagen Recent Development
 Table 102. Eli Lilly Company Details
 Table 103. Eli Lilly Business Overview
 Table 104. Eli Lilly Monoclonal Antibody Drugs for Cancer Product
 Table 105. Eli Lilly Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025) & (US$ Million)
 Table 106. Eli Lilly Recent Development
 Table 107. Ono Pharmaceutical Company Details
 Table 108. Ono Pharmaceutical Business Overview
 Table 109. Ono Pharmaceutical Monoclonal Antibody Drugs for Cancer Product
 Table 110. Ono Pharmaceutical Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025) & (US$ Million)
 Table 111. Ono Pharmaceutical Recent Development
 Table 112. Pfizer Company Details
 Table 113. Pfizer Business Overview
 Table 114. Pfizer Monoclonal Antibody Drugs for Cancer Product
 Table 115. Pfizer Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025) & (US$ Million)
 Table 116. Pfizer Recent Development
 Table 117. Regeneron Company Details
 Table 118. Regeneron Business Overview
 Table 119. Regeneron Monoclonal Antibody Drugs for Cancer Product
 Table 120. Regeneron Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025) & (US$ Million)
 Table 121. Regeneron Recent Development
 Table 122. Innovent Company Details
 Table 123. Innovent Business Overview
 Table 124. Innovent Monoclonal Antibody Drugs for Cancer Product
 Table 125. Innovent Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025) & (US$ Million)
 Table 126. Innovent Recent Development
 Table 127. Hengrui Medicine Company Details
 Table 128. Hengrui Medicine Business Overview
 Table 129. Hengrui Medicine Monoclonal Antibody Drugs for Cancer Product
 Table 130. Hengrui Medicine Revenue in Monoclonal Antibody Drugs for Cancer Business (2020-2025) & (US$ Million)
 Table 131. Hengrui Medicine Recent Development
 Table 132. Research Programs/Design for This Report
 Table 133. Key Data Information from Secondary Sources
 Table 134. Key Data Information from Primary Sources
 Table 135. Authors List of This Report


List of Figures
 Figure 1. Monoclonal Antibody Drugs for Cancer Picture
 Figure 2. Global Monoclonal Antibody Drugs for Cancer Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Monoclonal Antibody Drugs for Cancer Market Share by Type: 2024 VS 2031
 Figure 4. Mouse-derived Antibodies Features
 Figure 5. Chimeric Antibodies Features
 Figure 6. Humanized Antibodies Features
 Figure 7. Global Monoclonal Antibody Drugs for Cancer Market Size by Application (2020-2031) & (US$ Million)
 Figure 8. Global Monoclonal Antibody Drugs for Cancer Market Share by Application: 2024 VS 2031
 Figure 9. Lung Cancer Case Studies
 Figure 10. Breast Cancer Case Studies
 Figure 11. Prostate Cancer Case Studies
 Figure 12. Blood-related Cancer Case Studies
 Figure 13. Other Case Studies
 Figure 14. Monoclonal Antibody Drugs for Cancer Report Years Considered
 Figure 15. Global Monoclonal Antibody Drugs for Cancer Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 16. Global Monoclonal Antibody Drugs for Cancer Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global Monoclonal Antibody Drugs for Cancer Market Share by Region: 2024 VS 2031
 Figure 18. Global Monoclonal Antibody Drugs for Cancer Market Share by Players in 2024
 Figure 19. Global Top Monoclonal Antibody Drugs for Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibody Drugs for Cancer as of 2024)
 Figure 20. The Top 10 and 5 Players Market Share by Monoclonal Antibody Drugs for Cancer Revenue in 2024
 Figure 21. North America Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. North America Monoclonal Antibody Drugs for Cancer Market Share by Country (2020-2031)
 Figure 23. United States Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Canada Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Europe Monoclonal Antibody Drugs for Cancer Market Share by Country (2020-2031)
 Figure 27. Germany Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. France Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. U.K. Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Italy Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Russia Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Nordic Countries Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Asia-Pacific Monoclonal Antibody Drugs for Cancer Market Share by Region (2020-2031)
 Figure 35. China Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Japan Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. South Korea Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Southeast Asia Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. India Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Australia Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Latin America Monoclonal Antibody Drugs for Cancer Market Share by Country (2020-2031)
 Figure 43. Mexico Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Brazil Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Middle East & Africa Monoclonal Antibody Drugs for Cancer Market Share by Country (2020-2031)
 Figure 47. Turkey Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Saudi Arabia Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. UAE Monoclonal Antibody Drugs for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. Johnson & Johnson Revenue Growth Rate in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
 Figure 51. Novartis Revenue Growth Rate in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
 Figure 52. Gilead Sciences Revenue Growth Rate in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
 Figure 53. Roche Revenue Growth Rate in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
 Figure 54. Bristol-Myers Squibb Revenue Growth Rate in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
 Figure 55. Amgen Revenue Growth Rate in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
 Figure 56. AstraZeneca Revenue Growth Rate in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
 Figure 57. Merck & Co Revenue Growth Rate in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
 Figure 58. Takeda Revenue Growth Rate in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
 Figure 59. Merck KGaA Revenue Growth Rate in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
 Figure 60. Seagen Revenue Growth Rate in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
 Figure 61. Eli Lilly Revenue Growth Rate in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
 Figure 62. Ono Pharmaceutical Revenue Growth Rate in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
 Figure 63. Pfizer Revenue Growth Rate in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
 Figure 64. Regeneron Revenue Growth Rate in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
 Figure 65. Innovent Revenue Growth Rate in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
 Figure 66. Hengrui Medicine Revenue Growth Rate in Monoclonal Antibody Drugs for Cancer Business (2020-2025)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Global Therapeutic Monoclonal Antibodies Drug Market Research Report 2024
Global Therapeutic Monoclonal Antibodies Market Research Report 2024
Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Insights Forecast to 2030
Global Monoclonal Antibody for Gastric Cancer Market Research Report 2024
Global Small Molecule Targeted Cancer Therapy Market Research Report 2025
Global Anti CD20 Monoclonal Antibodies Market Research Report 2024
Global Conjugated Monoclonal Antibodies Market Research Report 2024
Global Hepatocellular Carcinoma Monoclonal Antibody Market Research Report 2025
Global Aβ Monoclonal Antibody Drug Market Research Report 2024
Global Arthritis Monoclonal Antibodies Market Research Report 2024
Monoclonal Antibody Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Biologics Monoclonal Antibodies Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Monoclonal Antibodies Product Market Research Report 2024
Global Monoclonal Antibodies for Non small Cell Lung Cancer Market Research Report 2025
Global Anticancer Drugs Market Research Report 2025
Global Combination Antibody Therapy Market Research Report 2024
Global Next Generation Monoclonal Antibodies Market Research Report 2024
Global Cancer Targeted Drug Market Research Report 2025
Global Targeted Antitumor Drugs Market Research Report 2025
Global Cancer Targeted Small Molecule Therapy Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions